GlaxoSmithKline Plc is recalling the company’s heartburn medicine Zantac as a “precautionary measure” due to a probable cancer-causing impurity in the drug, Britain’s medicines watchdog said.
The FDA found “unacceptable levels” of a cancer-causing impurity in limited testing using low-heat method of samples of heartburn medicines such as Zantac containing the ingredient ranitidine.
